Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2026)
Teva Pharmaceutical Industries (TEVA) recorded quarterly Income from Continuing Operations of 370000000.0 in Q1 2026, down 21.28% on a QoQ basis from 470000000.0 in Q4 2025, and up 68.18% year-over-year from 220000000.0 in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Teva Pharmaceutical Industries has disclosed Income from Continuing Operations across 11 years of filings, most recently posting 370000000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 68.18% year-over-year to 370000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1553000000.0 (up 217.3% YoY) and the FY2025 annual result came in at 1403000000.0, up 171.58% from the prior year.
- Income from Continuing Operations declined to 370000000.0 in Q1 2026, from 470000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 519000000.0 in Q1 2024 and troughed at 1334000000.0 in Q4 2022.
- A 5-year average of 140647058.82 and a median of 64000000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1286.59% — and 2024, when it surged 305.14%.
- Tracing TEVA's Income from Continuing Operations over 5 years: stood at 1334000000.0 in 2022, then surged by 134.93% to 466000000.0 in 2023, then slumped by 159.01% to 275000000.0 in 2024, then soared by 270.91% to 470000000.0 in 2025, then declined by 21.28% to 370000000.0 in 2026.
- Business Quant data shows TEVA's Income from Continuing Operations at 370000000.0 in Q1 2026, 470000000.0 in Q4 2025, and 432000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370.00 Mn |
| Dec 31, 2025 | 470.00 Mn |
| Sep 30, 2025 | 432.00 Mn |
| Jun 30, 2025 | 281.00 Mn |
| Mar 31, 2025 | 220.00 Mn |
| Dec 31, 2024 | -275.00 Mn |
| Sep 30, 2024 | -393.00 Mn |
| Jun 30, 2024 | -876.00 Mn |
| Mar 31, 2024 | 519.00 Mn |
| Dec 31, 2023 | 466.00 Mn |
| Sep 30, 2023 | 76.00 Mn |
| Jun 30, 2023 | -907.00 Mn |
| Mar 31, 2023 | -253.00 Mn |
| Dec 31, 2022 | -1.33 Bn |
| Sep 30, 2022 | 64.00 Mn |
| Jun 30, 2022 | -278.00 Mn |
| Mar 31, 2022 | -973.00 Mn |
| Dec 31, 2021 | -151.00 Mn |
| Sep 30, 2021 | 306.00 Mn |
| Jun 30, 2021 | 210.00 Mn |